tiprankstipranks
Adaptive Biotechnologies announces launch of clonoSEQ
The Fly

Adaptive Biotechnologies announces launch of clonoSEQ

Adaptive Biotechnologies announced the launch of its clonoSEQ Assay to detect minimal residual disease, MRD, in blood for patients with diffuse large B-cell lymphoma, DLBCL. clonoSEQ can assess a patient’s MRD status in DLBCL by measuring ctDNA, the fragments of DNA released into the blood from dying cancer cells which can serve as a measure of tumor burden. clonoSEQ is available in DLBCL as a CLIA-validated laboratory developed test, and beginning this week the company will accept DLBCL blood samples in Streck tubes. "We are excited to continue to expand access to clonoSEQ as a highly specific and less invasive tool for DLBCL monitoring which will complement the current standard imaging methods," said Nitin Sood, chief commercial officer, MRD, Adaptive Biotechnologies. "By measuring ctDNA in blood, clonoSEQ provides clinicians with a sensitive and quantitative assessment of disease burden so that they can detect relapse sooner and are better equipped to create a more precise treatment plan for each patient."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ADPT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles